Does State Medicaid Cover Farxiga (Dapagliflozin)?

How Medicaid Covers Farxiga: The Basics

Medicaid is jointly funded by states and the federal government, so each state runs its own formulary and writes its own prior-authorization (PA) policies. Federal law requires states to cover all drugs from manufacturers who participate in the Medicaid Drug Rebate Program, which AstraZeneca does, but states retain wide authority to manage utilization through PAs, step therapy, and quantity limits. [1] For Farxiga specifically, the practical result is that your ZIP code matters as much as your diagnosis.

The FDA approved dapagliflozin for type 2 diabetes (T2D) in 2014, for heart failure with reduced ejection fraction (HFrEF) in 2020, and for CKD in 2021. [2] Each additional indication reset the coverage conversation at the state level, because states revise formulary tiers and PA criteria on their own schedules, which can lag FDA approvals by 12 to 24 months.

A 2022 analysis published in JAMA Network Open found that SGLT2 inhibitor access in Medicaid varied substantially across states, with some states covering the class broadly and others restricting it to patients who had already tried two or more older agents. [3] That pattern holds today.

Farxiga Coverage for Type 2 Diabetes

T2D coverage is the strongest and most consistent indication across state Medicaid programs. Nearly every state includes dapagliflozin on its formulary for T2D, though the tier and PA requirements differ. Most states place Farxiga on a non-preferred brand tier, which means a PA or step-therapy requirement rather than automatic dispensing. [4]

Typical PA criteria for T2D across states include:

• A confirmed T2D diagnosis with HbA1c at or above 7.0% (some states use 7.5% or 8.0%)
• Documentation that the patient has tried and failed, or has a contraindication to, metformin at a maximally tolerated dose for at least 90 days
• A prescribing provider note that a generic SGLT2 inhibitor (where available) or an older agent such as a sulfonylurea is not appropriate

The American Diabetes Association 2024 Standards of Care recommend SGLT2 inhibitors as preferred add-on agents for T2D patients with established cardiovascular disease, HF, or CKD, specifically citing their kidney- and heart-protective benefits. [5] Presenting this guideline language in a PA request strengthens the clinical justification.

Dapagliflozin's cardiovascular outcome data in T2D come from the DECLARE-TIMI 58 trial (N = 17,160), which showed a statistically significant reduction in the composite of cardiovascular death or worsening heart failure (HR 0.83 to 95% CI 0.73 to 0.95, P<0.005) versus placebo. [6] Including this trial result in a PA or appeal submission directly counters any insurer argument that Farxiga is not medically necessary compared with cheaper alternatives.

Farxiga Coverage for Heart Failure

Heart failure coverage is where state Medicaid programs diverge most sharply. Some states added a specific HF PA pathway after the 2020 FDA approval; others have not updated their SGLT2 policies at all and still process HF requests under a T2D pathway that requires a diabetes diagnosis the patient does not have.

The DAPA-HF trial (N = 4,744) demonstrated that dapagliflozin 10 mg daily reduced the composite of worsening HF or cardiovascular death by 26% (HR 0.74 to 95% CI 0.65 to 0.85, P<0.001) in patients with HFrEF, including the 42% of participants who did not have T2D. [7] This finding is the cornerstone of the FDA's HF label and should be referenced explicitly in any PA or appeal submission for a non-diabetic heart failure patient. [2]

The EMPEROR-Reduced trial, which studied empagliflozin rather than dapagliflozin but is in the same drug class, and the EMPEROR-Preserved trial together helped establish the class effect that extends to HF with preserved ejection fraction (HFpEF). The FDA approved dapagliflozin for HFpEF in 2023, citing the DELIVER trial (N = 6,263), where dapagliflozin reduced the primary endpoint by 18% (HR 0.82 to 95% CI 0.73 to 0.92, P<0.001). [8] Many state Medicaid programs have not yet added explicit HFpEF language to their PA criteria, which creates denial risk even when the FDA label supports the prescription.

AHA/ACC 2022 Heart Failure Guidelines give SGLT2 inhibitors a Class I recommendation (Level of Evidence A) for patients with symptomatic HFrEF to reduce HF hospitalization and cardiovascular death, regardless of whether diabetes is present. [9] Citing the guideline class and evidence level in your PA letter carries weight with Medicaid medical reviewers.

Farxiga Coverage for Chronic Kidney Disease

CKD coverage through state Medicaid is expanding but remains inconsistent. The DAPA-CKD trial (N = 4,304) showed that dapagliflozin reduced the composite of sustained 50% decline in eGFR, end-stage kidney disease, or kidney or cardiovascular death by 39% (HR 0.61 to 95% CI 0.51 to 0.72, P<0.001), with benefit seen in both diabetic and non-diabetic CKD patients. [10] The FDA approved the CKD indication in April 2021 specifically for adults with CKD at risk of progression, regardless of T2D status. [2]

State Medicaid PA criteria for CKD commonly require:

• eGFR between 25 and 75 mL/min/1.73m² at baseline (matching the DAPA-CKD enrollment criteria)
• Urine albumin-to-creatinine ratio (UACR) above 200 mg/g
• Documentation of maximum tolerated ACE inhibitor or ARB use
• Nephrology or primary care attestation that the patient has CKD stage 3a to 3b or higher

KDIGO 2022 Clinical Practice Guidelines for CKD recommend SGLT2 inhibitors for all adults with T2D and CKD (eGFR ≥ 20 mL/min/1.73m²) as well as for adults without T2D who have CKD and UACR ≥ 200 mg/g. [11] KDIGO's categorical language ("we recommend") provides strong formulary-review support and should be quoted directly in PA requests.

Step Therapy Requirements

Step therapy is a Medicaid policy that requires a patient to try and fail a lower-cost drug before the plan will cover the requested agent. For Farxiga, step therapy is most common in the T2D indication.

Most states with step therapy for SGLT2 inhibitors require at least one of the following prior trials:

• Metformin (immediate-release or extended-release) at the maximally tolerated dose for 60 to 90 days
• A sulfonylurea such as glipizide or glimepiride for 90 days
• In some states, a DPP-4 inhibitor such as sitagliptin

For HF and CKD indications in patients without diabetes, step therapy is less common but not absent. A handful of states require documented failure of or contraindication to guideline-directed medical therapy (GDMT) before approving an SGLT2 inhibitor for HF. The ACC/AHA definition of GDMT for HFrEF includes beta-blockers, ACE inhibitors or ARBs or ARNI, and mineralocorticoid receptor antagonists. [9] Showing that the patient is already on optimized GDMT is often sufficient to satisfy the step-therapy requirement without an additional trial period.

The HealthRX Step-Therapy Response Framework for Farxiga PA Submissions

1. State the clinical indication precisely (T2D with HbA1c X%, HFrEF with EF X%, CKD stage X with UACR X mg/g).
2. List every previously tried agent with start date, stop date, dose, and reason for discontinuation or inadequate response.
3. Cite the relevant RCT (DECLARE-TIMI 58 [6], DAPA-HF [7], DELIVER [8], or DAPA-CKD [10]) and guideline class (ADA [5], AHA/ACC [9], or KDIGO [11]).
4. For HF or CKD without T2D, explicitly note that the FDA label does not require a diabetes diagnosis. [2]
5. Include a treating-physician attestation that step agents were tried or are contraindicated.

How to Appeal a Medicaid Denial of Farxiga

Federal Medicaid regulations require states to provide a fair-hearing process when a coverage request is denied. [12] You have the right to a state fair hearing, and in most states you must request it within 90 days of the denial notice.

The appeal process typically follows this sequence:

Step 1. Internal reconsideration. File an internal appeal with the managed-care organization (MCO) or the state Medicaid agency within 10 to 30 days of denial (the deadline varies by state). Attach the prescriber's clinical letter, the relevant trial data, and the applicable guideline text.

Step 2. External review. If the internal appeal fails, most states offer an independent medical review by a board-certified specialist not affiliated with the insurer. External review organizations are required to apply evidence-based criteria. Presenting DAPA-HF or DAPA-CKD data at this stage meaningfully improves approval rates.

Step 3. State fair hearing. If external review upholds the denial, you may request a formal administrative hearing before a Medicaid hearing officer. You or your provider can appear, present evidence, and cross-examine the insurer's medical reviewer. The federal requirement under 42 CFR 431.220 is that a decision be issued within 90 days of the hearing request. [12]

Step 4. State court. Judicial review of a hearing officer's decision is available in all states but is rarely necessary. The fair-hearing stage resolves most Farxiga denials when clinical documentation is thorough.

A 2021 study in Health Affairs (N = 1,152 appeals across six state Medicaid programs) found that approximately 39% of denied specialty drug appeals were overturned at the internal review or external review stage when the submission included a peer-reviewed clinical trial citation. [13] That figure underscores why trial-level evidence in the appeal letter changes outcomes.

Farxiga for Weight Loss and Medicaid

Farxiga is not FDA-approved for weight loss or obesity, and state Medicaid programs almost never cover it for that indication. Dapagliflozin produces modest weight reduction of approximately 2 to 3 kg as a secondary effect in T2D trials, but the FDA label does not list weight management as an approved use. [2]

Fewer than half of state Medicaid programs cover any GLP-1 receptor agonist or SGLT2 inhibitor specifically for obesity. Coverage for obesity pharmacotherapy in Medicaid has been growing since the AOM Act proposals in Congress and since CMS signaled openness to broader coverage, but as of 2025 the majority of states still exclude weight-loss-only prescriptions for this drug class. [14] If a patient has T2D and wishes to use Farxiga partly for its weight effects, the T2D indication is the appropriate coverage pathway.

Manufacturer Savings Programs and Medicaid

The AstraZeneca patient assistance program, AZ&Me, provides Farxiga at no cost to qualifying uninsured or underinsured patients who meet income thresholds. [15] The HealthRX medical team recommends checking eligibility if a patient is in a coverage gap.

Federal anti-kickback law (42 U.S.C. § 1320a-7b) prohibits using manufacturer copay cards or savings cards to reduce out-of-pocket costs for Medicaid beneficiaries. Using a coupon card on a Medicaid claim is a federal compliance violation and can expose both the pharmacy and the prescriber to liability. The AZ&Me free-drug program, however, is separate from copay coupons and is structured specifically for patients who lack insurance coverage, so it may be available to a Medicaid patient whose specific claim is denied and not covered. [15]

What to Do If Your State Does Not Cover Farxiga

If your state Medicaid denies Farxiga after exhausting appeals, several options exist. First, ask the prescriber whether empagliflozin (Jardiance) or canagliflozin (Invokana) is on a preferred formulary tier for the same indication. Head-to-head data for SGLT2 inhibitors across indications are limited, but class-effect evidence from EMPA-REG OUTCOME [16] and CANVAS [17] may support switching. Second, enroll in the AZ&Me program for a supply of Farxiga while the coverage situation is resolved. [15] Third, contact a patient advocacy organization. The National Kidney Foundation and the American Heart Association both maintain coverage advocacy resources for CKD and HF patients denied evidence-based therapies.

Patients with T2D who are denied Farxiga but have a documented cardiovascular event or CKD may also qualify for Medicaid exceptions under the ADA Standards of Care recommendation that SGLT2 inhibitors be prioritized in these subgroups regardless of HbA1c. [5] Framing the PA as a cardiovascular-risk-reduction or renal-protection request rather than a glucose-lowering request sometimes moves a denial to an approval without a formal appeal.

For CKD patients specifically, a 2023 NEJM Evidence analysis noted that the absolute risk reduction in DAPA-CKD corresponded to a number needed to treat (NNT) of 19 over 2.4 years to prevent one primary composite event, a figure that compares favorably with NNTs for drugs routinely covered without PA in most Medicaid programs. [18] Presenting NNT-level evidence in a formulary-exception request gives the Medicaid medical director a concrete, evidence-calibrated reason to approve.